H.B. Fuller’s board has rejected an unsolicited proposal from activist investor Ancora Holdings Group to acquire the company’s Building Adhesive Solutions (BAS) business for as much as $1.2 billion in cash. The decision sets up another confrontation between the adhesives manufacturer and an activist investor that has been pushing the company to rethink its strategy and portfolio.
The dispute is not simply about one business unit. It reflects a broader question facing H.B. Fuller: Should the company sell a lower-margin division to reduce debt and sharpen its focus, or retain the business as part of a diversified adhesives portfolio?
Ancora believes the answer is clear. H.B. Fuller’s board apparently disagrees.
Ancora’s $1.1 Billion to $1.2 Billion Proposal
Ancora publicly proposed buying H.B. Fuller’s Building Adhesive Solutions segment on Aug. 12.
The activist investor offered between $1.1 billion and $1.2 billion in cash, arguing that a sale would benefit H.B. Fuller shareholders while helping the company strengthen its balance sheet. H.B. Fuller confirmed at the time that it had received the unsolicited proposal and said its board would evaluate it with financial and legal advisers.
Ancora described the transaction as a potentially attractive solution because it could provide H.B. Fuller with immediate cash while allowing management to concentrate on other businesses and its broader strategic plans.
The board has now rejected that argument.
Why Ancora Wants the Business Sold
Ancora’s case rests on several points.
First, the sale could help H.B. Fuller reduce debt.
Second, management could concentrate more heavily on integrating its planned acquisition of Advanced Medical Solutions.
Third, Ancora argues that BAS has relatively lower margins and operates in a fragmented market, making it a logical candidate for divestiture.
Finally, the activist investor believes selling the division could unlock value that is not currently reflected in H.B. Fuller’s share price.
This is a classic activist-investor argument: a company may be worth more if its businesses are separated than if they remain together.
H.B. Fuller Sees Value in Keeping BAS
The board’s rejection suggests that management does not believe the $1.1 billion-to-$1.2 billion offer adequately compensates shareholders for giving up BAS.
That is an important distinction.
A business does not have to be the company’s fastest-growing or highest-margin division to be strategically valuable.
BAS could provide customer relationships, manufacturing capabilities, geographic reach and cross-selling opportunities that are difficult to capture in a simple financial valuation.
Selling it would generate cash immediately, but it would also permanently remove a source of revenue and earnings.
BAS Is Already Under Pressure
There is, however, some evidence supporting Ancora’s criticism.
H.B. Fuller’s own first-quarter 2026 presentation showed Building Adhesive Solutions organic revenue declining 5.1% year over year. Adjusted EBITDA declined 1%, while margins were roughly flat. Pricing and raw-material actions and restructuring savings helped offset volume weakness.
That performance gives Ancora a straightforward argument.
If BAS is producing weaker growth and lower margins than other parts of the business, why should H.B. Fuller continue allocating capital to it?
From an activist perspective, selling a slower-performing division can allow management to focus resources on businesses with better growth opportunities.
But the counterargument is equally straightforward: weak current performance does not necessarily mean the asset should be sold.
The Advanced Medical Solutions Deal Changes the Calculation
H.B. Fuller is also in the middle of another major strategic move.
The company agreed to acquire Advanced Medical Solutions Group, a UK-based medical technology and healthcare company, for approximately £659 million in equity value and about £715 million in enterprise value. Shareholders of Advanced Medical Solutions approved the transaction in August.
This acquisition is important because it expands H.B. Fuller’s exposure to medical adhesives and related technologies.
Ancora argues that selling BAS would help H.B. Fuller finance and integrate this acquisition.
The activist investor therefore sees the two transactions as complementary:
Sell a lower-margin business and use the proceeds to strengthen the balance sheet while investing in higher-growth areas.
Management evidently believes BAS is worth more inside the company than Ancora’s offer suggests.
Project Quantum Leap Adds Another Layer
Ancora also referenced H.B. Fuller’s Project Quantum Leap, the company’s broader strategic initiative.
The activist investor argued that selling BAS could give management greater freedom to execute that strategy while reducing the complexity of running the business.
That argument reflects a broader trend among industrial companies.
When companies accumulate too many businesses, management attention can become fragmented.
A narrower portfolio can make it easier to allocate capital toward the highest-return opportunities.
But portfolio simplification can also remove diversification.
The Activist Fight Is Bigger Than BAS
The rejection is unlikely to end the dispute.
Ancora has already demonstrated that it is willing to publicly pressure H.B. Fuller.
The investment firm has about $11.7 billion in assets under management and has described itself as a significant H.B. Fuller shareholder.
Its involvement means the company is facing pressure not only to operate its businesses efficiently but also to justify why each business belongs inside the corporate structure.
That can lead to further demands for strategic reviews, asset sales or even broader changes to the company.
Another Activist Investor Is Watching
Ancora is not the only shareholder pushing H.B. Fuller.
Engine Capital, which owns roughly 2% of the company, has also urged H.B. Fuller to test the market for BAS and consider alternatives for the division and potentially the entire company.
That increases the pressure on management.
When multiple activist investors begin questioning the same asset, the board has to provide a convincing explanation for keeping it.
The company cannot simply dismiss the proposals without demonstrating why retaining BAS creates greater long-term value.
The Real Question Is Valuation
At the center of the dispute is valuation.
Ancora is effectively saying that BAS can be sold for $1.1 billion to $1.2 billion and that the proceeds would be more valuable to shareholders if H.B. Fuller used them elsewhere.
H.B. Fuller must therefore believe one of three things:
- BAS is worth more than Ancora’s offer.
- Keeping BAS creates strategic benefits that a sale would eliminate.
- The company can improve BAS’s financial performance enough to justify retaining it.
If none of those arguments proves true, shareholder pressure could intensify.
Selling Could Strengthen the Balance Sheet
One of Ancora’s strongest arguments is financial.
A $1.2 billion cash transaction could provide H.B. Fuller with substantial funds for debt reduction.
That matters because industrial acquisitions can increase leverage.
H.B. Fuller is simultaneously expanding its medical adhesives exposure through Advanced Medical Solutions.
Reducing debt after that transaction could improve financial flexibility and potentially lower interest costs.
It could also give the company more capacity for future investment.
But Debt Reduction Isn’t the Only Use of Cash
H.B. Fuller could also use proceeds to invest in its remaining businesses.
That could include research and development, manufacturing upgrades, acquisitions or shareholder returns.
The value of a BAS sale therefore depends partly on what management does with the cash afterward.
A divestiture only creates value if the capital is redeployed effectively.
Otherwise, shareholders simply lose an operating asset.
BAS Could Still Have Strategic Value
The strongest argument for keeping BAS is that its current performance may not reflect its long-term potential.
Building adhesives serve a wide range of applications, including roofing, building envelopes, infrastructure, glass and wood and composite products.
The segment therefore operates across multiple construction and industrial markets.
A temporary decline in organic revenue does not necessarily mean the underlying market opportunity has disappeared.
If construction activity improves, BAS could recover.
Selling during a weak period could potentially mean giving up future upside.
The Risk of Selling at the Wrong Time
This is one of the biggest weaknesses in Ancora’s argument.
Activists often focus on what an asset is worth today.
Management may be more interested in what it could be worth after restructuring, investment or market recovery.
If H.B. Fuller sells BAS and the business subsequently performs strongly under a new owner, shareholders could criticize the board for selling too cheaply.
That is why portfolio decisions are rarely as simple as comparing an offer with current earnings.
The Activist Argument Still Has Teeth
Despite that, Ancora has identified a legitimate problem.
BAS is not currently producing the strongest growth within H.B. Fuller.
Meanwhile, the company is committing capital to medical adhesives and other strategic initiatives.
That creates an opportunity cost.
Every dollar invested in BAS is a dollar that cannot be invested elsewhere.
Every management hour spent running BAS is an hour that cannot be spent integrating Advanced Medical Solutions or developing higher-growth businesses.
That is the core of the activist case.
What Investors Should Watch Next
The next phase of the dispute could revolve around several issues.
BAS Valuation
Investors will want to know how much H.B. Fuller believes the business is actually worth.
Debt Levels
The company’s leverage and financing needs will determine how attractive a $1.2 billion cash injection would be.
Advanced Medical Solutions Integration
If the acquisition performs well, management’s argument for focusing on medical adhesives becomes stronger.
BAS Margins
If BAS margins improve significantly, Ancora’s case weakens.
Shareholder Support
The most important question may be whether other investors agree with Ancora.
Activists become more powerful when they can convince institutional shareholders that management is destroying value.
A Rejection Does Not End the Story
H.B. Fuller’s decision to reject Ancora’s bid is not necessarily the final word.
Ancora could increase pressure through public campaigns, shareholder proposals or demands for further strategic reviews.
Engine Capital’s involvement could add additional momentum.
Management therefore has an incentive to demonstrate that keeping BAS will create more value than selling it.
The company may ultimately need to show investors concrete evidence rather than relying on general strategic arguments.
Conclusion
H.B. Fuller’s rejection of Ancora’s offer for its Building Adhesive Solutions business marks another stage in an increasingly important shareholder battle.
Ancora offered as much as $1.2 billion in cash and argued that selling BAS would allow H.B. Fuller to reduce debt, simplify its portfolio and focus on higher-growth opportunities such as medical adhesives.
There is a credible financial argument behind that proposal.
BAS recently experienced declining organic revenue, and its margins have not shown the kind of improvement that would immediately justify aggressive capital allocation.
But H.B. Fuller’s decision to reject the offer suggests management believes the division’s strategic and long-term value exceeds what Ancora is offering.
The crucial issue now is not whether Ancora or H.B. Fuller is automatically right.
It is whether the company can prove that retaining BAS will create more shareholder value than selling it.
If BAS recovers and becomes a stronger contributor to earnings, management’s decision will look justified.
If performance remains weak while H.B. Fuller carries higher debt and struggles to integrate its medical-adhesives acquisition, activists will have a much stronger case.
For investors, the dispute is therefore becoming a test of capital allocation.
H.B. Fuller has to decide whether it is better to remain a broad adhesives company or become a more focused business built around the areas where management believes it can generate the highest returns.
That decision could ultimately determine whether the company’s current strategy creates value—or whether another portfolio restructuring becomes unavoidable.
